175 related articles for article (PubMed ID: 30180951)
1. An experimental study of ovarian cancer imaging and therapy by paclitaxel-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound.
Gao Y; Chen S; Li W; Wang H; Xiao K; Wu L; Li Y; Li H; Li H; Zhu Y
Biochem Biophys Res Commun; 2018 Sep; 504(1):203-210. PubMed ID: 30180951
[TBL] [Abstract][Full Text] [Related]
2. Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.
Zhao H; Wu M; Zhu L; Tian Y; Wu M; Li Y; Deng L; Jiang W; Shen W; Wang Z; Mei Z; Li P; Ran H; Zhou Z; Ren J
Theranostics; 2018; 8(7):1892-1910. PubMed ID: 29556363
[No Abstract] [Full Text] [Related]
3. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
4. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles for the treatment of intraperitoneal ovarian cancer xenografts.
Pu C; Chang S; Sun J; Zhu S; Liu H; Zhu Y; Wang Z; Xu RX
Mol Pharm; 2014 Jan; 11(1):49-58. PubMed ID: 24237050
[TBL] [Abstract][Full Text] [Related]
6. Peptide-Functionalized Phase-Transformation Nanoparticles for Low Intensity Focused Ultrasound-Assisted Tumor Imaging and Therapy.
Zhu L; Zhao H; Zhou Z; Xia Y; Wang Z; Ran H; Li P; Ren J
Nano Lett; 2018 Mar; 18(3):1831-1841. PubMed ID: 29419305
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro.
Ma J; Shen M; Xu CS; Sun Y; Duan YR; Du LF
Oncotarget; 2016 Nov; 7(48):80008-80018. PubMed ID: 27835907
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer.
Zhai J; Luwor RB; Ahmed N; Escalona R; Tan FH; Fong C; Ratcliffe J; Scoble JA; Drummond CJ; Tran N
ACS Appl Mater Interfaces; 2018 Aug; 10(30):25174-25185. PubMed ID: 29963859
[TBL] [Abstract][Full Text] [Related]
9. Dual-mode imaging and therapeutic effects of drug-loaded phase-transition nanoparticles combined with near-infrared laser and low-intensity ultrasound on ovarian cancer.
Chen S; Liu Y; Zhu S; Chen C; Xie W; Xiao L; Zhu Y; Hao L; Wang Z; Sun J; Chang S
Drug Deliv; 2018 Nov; 25(1):1683-1693. PubMed ID: 30343601
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic Cancer.
Xing L; Shi Q; Zheng K; Shen M; Ma J; Li F; Liu Y; Lin L; Tu W; Duan Y; Du L
Theranostics; 2016; 6(10):1573-87. PubMed ID: 27446491
[TBL] [Abstract][Full Text] [Related]
11. A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity.
Jian Y; Zhao M; Cao J; Fan T; Bu W; Yang Y; Li W; Zhang W; Qiao Y; Wang J; Wen A
Drug Des Devel Ther; 2020; 14():2355-2370. PubMed ID: 32606603
[TBL] [Abstract][Full Text] [Related]
12. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
13. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
14. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma.
Pandey V; Gajbhiye KR; Soni V
Drug Deliv; 2015 Feb; 22(2):199-205. PubMed ID: 24467582
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Wang F; Li L; Liu B; Chen Z; Li C
Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
[TBL] [Abstract][Full Text] [Related]
16. Cellular uptake and antitumour activity of paclitaxel incorporated into trilaurin-based solid lipid nanoparticles in ovarian cancer.
Xu W; Lim SJ; Lee MK
J Microencapsul; 2013; 30(8):755-61. PubMed ID: 23594306
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy.
Oh KS; Song JY; Cho SH; Lee BS; Kim SY; Kim K; Jeon H; Kwon IC; Yuk SH
J Control Release; 2010 Dec; 148(3):344-50. PubMed ID: 20797418
[TBL] [Abstract][Full Text] [Related]
18. Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor.
Yang X; Shi X; Ji J; Zhai G
Drug Deliv; 2018 Nov; 25(1):780-796. PubMed ID: 29542333
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional theranostic contrast agent for photoacoustics- and ultrasound-based tumor diagnosis and ultrasound-stimulated local tumor therapy.
Moon H; Kang J; Sim C; Kim J; Lee H; Chang JH; Kim H
J Control Release; 2015 Nov; 218():63-71. PubMed ID: 26432554
[TBL] [Abstract][Full Text] [Related]
20. An optimized two-vial formulation lipid nanoemulsion of paclitaxel for targeted delivery to tumor.
Chen L; Chen B; Deng L; Gao B; Zhang Y; Wu C; Yu N; Zhou Q; Yao J; Chen J
Int J Pharm; 2017 Dec; 534(1-2):308-315. PubMed ID: 28986321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
